FoRx Therapeutics is a biotechnology company developing a new generation of cancer drugs focusing on novel DNA Replication Stress pathways.
FoRx Therapeutics has raised $50.0M in total funding. The most recent round was Series A. The last funding was announced in December 2025.
FoRx Therapeutics's investors include Pfizer, EQT Life Sciences, Pfizer Venture Investments, Omega Funds, M Ventures.
FoRx Therapeutics is headquartered in Basel, Switzerland.
FoRx Therapeutics is a biotechnology company developing a new generation of cancer drugs focusing on novel DNA Replication Stress pathways.
FoRx Therapeutics is at the Series A stage.
Free to use in articles, research, and reference works. Stable URL — will not change. Data on this page last updated .
"FoRx Therapeutics — Funding & Investors." VCBacked, December 18, 2025, https://www.vcbacked.co/company/forx-therapeutics. Accessed August 14, 2026.
VCBacked. (2025). FoRx Therapeutics — Funding & Investors. Retrieved August 14, 2026, from https://www.vcbacked.co/company/forx-therapeutics
{{cite web |title=FoRx Therapeutics — Funding & Investors |url=https://www.vcbacked.co/company/forx-therapeutics |website=VCBacked |access-date=August 14, 2026}}Profile data sourced and verified per the VCbacked methodology · Last funding round dated